Q1 Earnings Hit by $425M Greensill Litigation Charge Despite Revenue Growth
Summary
Marsh & McLennan reported Q1 2026 revenue growth, but a $425 million charge from the Greensill litigation caused a 12% drop in operating income and a 15% decline in diluted EPS.
Key Events
-
Q1 2026 Financial Performance
Consolidated revenue increased 8% (4% on an underlying basis) to $7.6 billion. However, operating income decreased 12% to $1.8 billion, and diluted EPS fell 15% to $2.36, compared to the prior year period.
-
Significant Greensill Litigation Charge
The company recorded a $425 million gross liability and legal expenses in Q1 2026 related to the ongoing Greensill litigation in Australia, which was the primary driver for the decline in profitability.
-
Share Repurchase Activity
Marsh & McLennan repurchased $750 million of its common stock in Q1 2026, with approximately $4.9 billion remaining under the existing authorization, continuing its capital return program.
-
Debt Management
The company issued $600 million in 4.950% senior notes due 2036 and repaid $600 million in 3.750% senior notes at maturity, actively managing its debt portfolio.
Analysis
Marsh & McLennan's first-quarter results show solid underlying revenue growth, but profitability was significantly impacted by a substantial $425 million charge related to the Greensill litigation. This legal liability led to a double-digit decline in operating income and diluted EPS, overshadowing the positive top-line performance. Investors should monitor the ongoing litigation's future impact and the progress of the 'Thrive' restructuring program, which is incurring costs while aiming for efficiency gains.
At the time of this filing, MRSH was trading at $177.00 on NYSE in the Finance sector, with a market capitalization of approximately $84.7B. The 52-week trading range was $164.89 to $239.34. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.